Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.

Also called NCT05731544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 443 participants (enrolled count) (from the registry)
Sponsor
Biomea Fusion Inc. (from the registry)
Registry
  • NCT NCT05731544
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05731544. Randomized; double masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2024-11-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
BMF-219
Intervention (Drug)
Placebo
Lead sponsor
Biomea Fusion Inc. (class: industry)

Record details

Record id
cardio:ct-nct05731544
Content hash
df14d7f4cc67d7edb56491916ab7421b65057cfc5b9643c0da1dc593d3a5326b